221 related articles for article (PubMed ID: 31952967)
1. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials.
Russo GI; Scandura C; Di Mauro M; Cacciamani G; Albersen M; Hatzichristodoulou G; Fode M; Capogrosso P; Cimino S; Marcelissen T; Cornu JN; Gacci M; Minervini A; Cocci A;
Eur Urol Focus; 2021 Mar; 7(2):420-431. PubMed ID: 31952967
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
[TBL] [Abstract][Full Text] [Related]
3. Serenoa repens for benign prostatic hyperplasia.
Tacklind J; Macdonald R; Rutks I; Stanke JU; Wilt TJ
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD001423. PubMed ID: 23235581
[TBL] [Abstract][Full Text] [Related]
4. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
Prostate; 2015 Dec; 75(16):1857-67. PubMed ID: 26306400
[TBL] [Abstract][Full Text] [Related]
5. Serenoa repens for benign prostatic hyperplasia.
Tacklind J; MacDonald R; Rutks I; Wilt TJ
Cochrane Database Syst Rev; 2009 Apr; (2):CD001423. PubMed ID: 19370565
[TBL] [Abstract][Full Text] [Related]
6. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
MacDonald R; Tacklind JW; Rutks I; Wilt TJ
BJU Int; 2012 Jun; 109(12):1756-61. PubMed ID: 22551330
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Novara G; Giannarini G; Alcaraz A; Cózar-Olmo JM; Descazeaud A; Montorsi F; Ficarra V
Eur Urol Focus; 2016 Dec; 2(5):553-561. PubMed ID: 28723522
[TBL] [Abstract][Full Text] [Related]
8. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement.
Franco JV; Trivisonno L; Sgarbossa NJ; Alvez GA; Fieiras C; Escobar Liquitay CM; Jung JH
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD001423. PubMed ID: 37345871
[TBL] [Abstract][Full Text] [Related]
9. Serenoa repens for benign prostatic hyperplasia.
Wilt T; Ishani A; Mac Donald R
Cochrane Database Syst Rev; 2002; (3):CD001423. PubMed ID: 12137626
[TBL] [Abstract][Full Text] [Related]
10. Phytotherapy for benign prostatic hyperplasia.
Wilt TJ; Ishani A; Rutks I; MacDonald R
Public Health Nutr; 2000 Dec; 3(4A):459-72. PubMed ID: 11276294
[TBL] [Abstract][Full Text] [Related]
11. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
[TBL] [Abstract][Full Text] [Related]
12. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine.
Ooi SL; Pak SC
J Altern Complement Med; 2017 Aug; 23(8):599-606. PubMed ID: 28436684
[TBL] [Abstract][Full Text] [Related]
13. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD010060. PubMed ID: 30480763
[